“When we look at H2, in fact, we expect a continuation of these very strong momentum that we've seen in H2 on smoke free. So we expect IQOS to continue to grow double digit in term of adjusted IMS.”

In context

“of those. When when when they become lapped into the base. Emmanuel Babeau: Yeah. I I think, you know, when when you look at the there are, of course, you know, a number of element that can distort, the the vision quarter on quarter, H2 versus H1, What we wanted to ensure that everybody understand is that in fact, the momentum in Q2 on smoke free is in fact even better than Q1. And Q1 was already very good. But in fact, in Q2, we've seen an acceleration of the IQOS in market sales. And, you know, we are nice to back to nice double digit growth Very nice and very powerful reacceleration of Zine in the US. Of course, you know, elsewhere ZYN and VIVA are growing very fast. But Q2, in fact, is a very nice acceleration on our smoke free business, and this is absolutely visible in our numbers. When we look at H2, in fact, we expect a continuation of these very strong momentum that we've seen in H2 on smoke free. So we expect IQOS to continue to grow double digit in term of adjusted IMS. We expect now that we have availability which is no longer an issue for ZYN in the US, expect the continuation of this very strong acceleration of ZYN in the US Again, I reported the 37% growth for the first two weeks of July. So H2 is starting on a good note for ZYN in in the U. S. So this momentum is unchanged, and we expect it to remain very strong. Certainly, what is gonna be less for favorable is the trend on combustible. We were almost flat minus 0.3% in volume in H1, and we expect 3% to 4% decline I've been explaining the driver for that. Despite that, we expect a growth on gross profit for combustible, but nevertheless at a lower level of course, than in in in H1. So this is one of the reasons for the differentiated performance in in in H2 versus H1 for what we can expect And then”